Lower risk of MACE and all-cause death in patients initiated on semaglutide 2.4 mg in routine clinical care: Results from the score study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)

Archives of cardiovascular diseases 2026

View at publisher

Authors: François Schiele, Zhenxiang Zhao, Jinlin Song, M. Faurby, W. Michalak, Yan Chen, James P. Boland, B.G. Smolarz, M N Kosiborod

DOI: 10.1016/j.acvd.2025.10.204

Cited by: 0

Fields of Study & Subjects

Diabetes Treatment and Management Bariatric Surgery and Outcomes Metabolism Diabetes and Cancer